

The Role of HbA1c in Severity and Mortality Rate of ST Segment Elevation Myocardial Infarction for Hospitalized Libyan Non-Diabetic Patients



Asgad Abdalgar^{1,2} and Hanan KG Altalhi^{1*}

¹Faculty of Medicine, University of Omar El Mukhtar, Libya

²Faculty of Medical Technology, University of Omar El Mukhtar, Libya

Submission: November 05, 2019; Published: December 03, 2019

*Corresponding author: Hanan KG Altalhi, Faculty of Medical Technology, University of Omar El Mukhtar, Albayda, Libya

Abstract

Background: The severity of coronary artery disease (CAD) is directly related to the quality of glucose control in diabetic patient. Additionally, diabetes is associated with increased mortality following acute myocardial infarction compared to general population.

Objectives: To evaluate the association of HbA1c level and severity of CAD, and outcome of non-diabetic patient with STEMI in our hospital.

Patients and Methods: 60 consecutive non-diabetic patient with acute ST elevation myocardial infarction were treated with thrombolytic therapy included in the present prospective study. Blood glucose and HbA1c level of all patients were measured within 3 hours of admission. Patient were divided in to 3 groups according to HbA1c level: with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American diabetes association) group (1) 6.5%, group (2) 6.5 to 8.5%, group (3) 8.5% and above. In hospital. mortality and morbidities of acute STEMI were compared between groups.

Result: The mean age was 63±15 year and mean body mass index was 26. 6±6 kg/m², 24 patients (40%) had history of hypertension, 27 patients (45%) of dyslipidemia, 36 patients (60%) were smoker. We found 45 patients with HbA1c ≤ 6.5%, 5 patients with HbA1c 6.5 -8.5 %, 10 patients with HbA1c ≥ 8.5%. There was strong correlation between admission of HbA1c and admission glucose level (P< 0.001). Infarct size as measured by peak creatinin kinase, was not correlated with HbA1c level.

Conclusion: HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality.

Keywords: Glycosylated hemoglobin; ST elevation myocardial infarction; Mortalities; Diabetes; Glucose metabolism; Coronary syndrome; Catecholamine level; Cardiovascular disease; Hemoglobinopathies; Hypothyroidism; Tumor; Connective tissue

Abbreviations: SCAD: Coronary Artery Disease; HbA1c: Glycosylated Hemoglobin; STEMI: ST Elevation Myocardial Infarction; ECG: Electrocardiography

Introduction

Patients with diabetes are at 3-4 times increased risk for cardiovascular mortality compared with non-diabetes [1]. In acute coronary syndrome, glucose metabolism is modified and stress hyperglycemia commonly occur secondary to increase catecholamine level [2]. In addition to the higher rate of acute ST- elevation myocardial infarction (STEMI) in diabetes, hyperglycemia is associated with poor prognosis in these patients [3-5].

Higher HbA1c level was associated with high cardiovascular disease and death [6]. There were some other studies supporting the association between admission serum HbA1c level and

increased long-term mortality of non-diabetic patients admitted with STEMI and higher rate CAD in these patients [7,8]. We have evaluated the association of admission level of HbA1c with the hospital outcome of non-diabetic patient with STEMI.

Patients and Methods

All patients of both sexes sustaining acute ST elevation myocardial infarction without diabetes were including in the study. Patients with sepsis, hemoglobinopathies or hypothyroidism, tumor, connective tissue diseases, those with sub-acute or chronic MI (longer than 48 hr between first symptom and admission) those with renal failure, hepatic failure

, iron deficiency anemia and those with past history of diabetes or used anti diabetic medication were excluded from the study.

Acute myocardial infarction was defined according to the (European Society of Cardiology and American College of Cardiology Criteria). Increased creatine kinase predominantly in the myocardial band fraction and or increased troponin I (creatin kinase 400 U /L or higher and or cardiac troponin I 2µg / L or higher), ischemic symptoms (mainly constrictive chest pain, lasting longer than 30 min), and or abnormal electrocardiography (ST elevation 1 mm or greater on at least two derivation). MI was defined as acute if the time elapsed between the first symptom and admission was 48 hr or less. Only patients who underwent thrombolytic treatment were included in the study.

All patients were in cardiac care unit, a brief history was obtained from each patient presenting with acute chest pain including presence of risk factors like smoking and hypertension, dyslipidemia and previous history of ischemic heart disease. Clinical examination was done emphasis on signs of cardiac failure, 12 leads electrocardiography (ECG) was done at cardiac care unit and blood sample were sent to laboratory, blood glucose and HbA1c level of all patients were measured within 3 hr of admission regardless of whether they had been fasting or not and for cardiac enzyme. The fasting lipid profile was determined on the morning following admission and included total cholesterol, high density lipoprotein and triglyceride.

All patients were considered for thrombolytic therapy (Injection streptokinase 1.5 million units over one hour) in the absence of all contraindication the management was according to standard treatment protocol. All patients underwent continues ECG monitoring for at least 48 hours on admission to cardiac care unit and daily during hospital stay.

Patients were divided into three groups according to the level of HbA1c with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American Diabetes Association 2010) for diagnosis and classification of diabetes mellitus. Patient with HbA1c level of 4.5% to 6.4 % group (1), patients with HbA1c level 6.5% to 8.5% group (2) and patients with HbA1c level higher than 8.5 % group 3).

None of these patients received glucose, Insulin or potassium infusion therapy during admission. All subjects were hospitalized one week after acute myocardial infarction and hospital records were reviewed at this time.

Selective coronary angiography was performed after 1 month. Coronary angiogram were analyzed by two experienced observers who were blinded to the identities and clinical information of the patients .Vessel scores were ranged from zero to three, according to the number of diseased major pericardial vessel with significant stenosis (greater than 50% stenosis of the lumen diameter).

Statistical analysis

Was performed by using SPSS software (Version 12) difference among groups was analyzed by (t-test) and P value 0.05 was considerable significant.

Result

Table 1: Total 60 patients with STEMT were studied. Patients were divided on the bases of admission HbA1c group (1) ≤ 6.5 %; group (2) 6.5-8.5 %; group 3 ≥ 8.5%. The clinical and biological characteristic according to HbA1c are summarized in Table 1. The mean age was 63±15 year and mean body mass index was 26. 6±6 kg/m², 24 (40%) had history of hypertension, 27 (45%) of dyslipidemia, 36 (60%) were smoker. We found 45 with HbA1c ≤ 6.5%; 5 with HbA1c 6.5-8.5%, 10 with HbA1c ≥ 8.5%.

Table 1: Clinical and biological characteristics of the study subjects. according to admission HbA1c level.

Level of Glycated Hemoglobin					
	All n=60	Group 1 <6.5% n=45	Group 2 6.5-8.5% N=5	Group 3 >8.5 N=10	P Value
Age(year)	63±15	61±15	60±17	70±10	0.02
Sex(M/F) n	48/12	40/5	3/2	7/3	0.4
Current or former smoker (%)	36(60)	29(65)	2(40)	6(60)	
BMI (kg/m ²)	26.6±6	26.1±5	26.7±4.2	29±4.9	0.05
Admission SBP (mmHg)	132±25	129±25	136±22	143±25	0.05
Admission DBP (mmHg)	72±18	72±15	71±14	76±23	0.05
Admission plasma glucose(mmol/L)	8.2±3.7	7.7±2.9	8.2±2.2	11.2±6.5	<0.0001
Total cholesterol(mmol/L)	6±1.2	6.1±1.3	6.3±0.9	5.5±1.1	0.01
HDL cholesterol (mmol/L)	1±0.4	1.3±0.4	1.2±0.1	1.2±0.3	0.27
Triglyceride (mmol/L)	1.53±0.89	1.47±0.86	1.88±0.89	1.56±0.99	0.36
Peak CK in first 24 hour (U/L)	903 (210-3256)	1979 (580-3227)	1500 (647-3000)	1486 (504-3126)	NS

Data are mean±SD, BMI: Body Mass Index ie body weight (kg) / height²(m²). SBP/ DBP: Systolic / Diastolic Blood Pressure; CK: Creatinin kinase.

There was strong correlation between admission HbA1c and admission glucose level (P< 0.0001). Infarct size as measured by peak creatinine kinase, was not correlated with HbA1c level.

Table 2: Patients were divided according to admission glucose [group (1), 6.9 mmol/L; group (2), 7 to 8.1 mmol/L; group (3), 8.2 to 9.5 mmol/L; group (4) ≥ 9.6 mmol/ L]. There was significant positive correlation between admission glucose and infarct size measured by peak creatinine kinase level (P<0.0001).

Table 2: Clinical outcome of non-diabetic patients based on quantities of admission plasma glucose.

Admission Glucose Level					
	IQR1 6.9 mmol/L	IQR2 7-8.1mmol/L	IQR3 8.2-9.5mmol/L	IQR4 ≥9.6mmol/L	P Value
Infarct size Peak.CK in the first 24 hr	530 (210-1150)	903 (327-2050)	1367 (564-2924)	1912 (827-3256)	<0.0001

IQR: Interquartile Range; CK: creatinine kinase. Value are expressed as median (IQR).

Table 3: At the end of fourth week coronary angiography performed in remaining 54 patients, revealed that there was

significant correlation between HbA1c level at admission and number of disease vessel(P=0.001).

Table 3: Angiographic data of patients according to HbA1c.

Level of Glycosylated Hemoglobin				
Number of diseased vessel N (%)	Group 1 <6.5% N=39	Group 2 6.5%-8.5% N=5	Group 3 >8.58.5% N=10	P Value
Single vessel	30(76.9%)	3(60%)	1(10%)	0
Double vessel	7(17.9%)	1(20%)	4(40%)	0.16
Triple vessel	2(5.1%)	1(20%)	5(50%)	0.001

Table 4: We found that patients who died by day 5 were significantly different from patients with non-lethal acute myocardial infarction, with regard to admission plasma glucose (16.6±5.4 vs 8.3±3.4 mmol/L , P=0.0001), age (74±10 vs 62±13 year, P=0.002).

enzymatic infarction size and lower left ventricular ejection fraction. This is because a stress response is accompanied by high level of catecholamine and cortisol and these hormones increase glucogenolysis and lipolysis and reduce insulin sensitivity, resulting in elevated glucose level [10]. There for, patients with elevated glucose level may represent with an increased stress response, due to more sever hemodynamic compromise or more extensive myocardial damage [11,12].

Table 4: Clinical characteristics of patients according to the mortality at 5 days after acute myocardial infarction.

	Dead by day 5 N=6	Alive by day 5 N=54	P Value
Age(year)	74±10	62±13	0.002
Sex (M/F)	6/0	42/12	0.33
Peak creatinin kinase (IU/L)	1068 (1120-3256)	825 (210-1860)	0.02
Admission plasma glucose (mmol/L)	16.6±5.4	8.3±3.4	0.0001
HbA1c	6.7±1.8	6.2±0.2	0.15

HbA1c: Glycosylated Hemoglobin

There was no significant difference in HbA1c value in the survivor and non-survivor (6.7±1.8 vs 6±0.2, P=0.15).

Elevated cytokine, particularly tumor necrosis factor-Alpha (TNF-α), also increase glucose level. TNF-α is released in AMI and directly decrease myocardial contractility, probably by inducing myocardial apoptosis [5,13]. TNF -α also cause impaired endothelial function [14]. This in turn, may be responsible for the impaired myocardial perfusion. We found positive correlation between peak creatinin kinase and admission plasma glucose concentration in our patients. Conversely, no correlation was found with HbA1c value. Although acute hyperglycemia at admission and during stay has clearly been associated with adverse outcome in patients with acute MI [7,15,16].

Discussion

The present study confirms previous observation in diabetic subjects suggesting that higher glucose level during AMI are associated with increased mortality [9]. In recent study, Timmer J et al, [7] reported that higher admission glucose level in non-diabetic patients treated with reperfusion therapy for ST segment elevation MI were associated with significantly larger

Our study shows admission HbA1c level are not associated with high mortality in non-diabetic STEMI population treated with streptokinase. In our study high HbA1c in non-diabetic patients associated with multi vessels involvement of coronary arteries. Similarly, Cak Mak et al, [17] reported a significant correlation between HbA1c level at admission and positive exercise that result after the four weeks follow up.

Hyperglycemia in STEMI patients was strongly associated with increased mortality within 5 days although there is clear

correlation between admission glucose and HbA1c level, they appear to represent related but different phenomena. Patients with elevated glucose level have larger MI area.

Recently a prospective cohort study showed that in non-diabetic general population, as elevated HbA1c level is a risk factor for the development of cardiovascular events independently of fasting glucose [6]. The international expert committee recommended the use of HbA1c in diagnosis diabetes with a cut-off 6.5 % [18].

The advantage of HbA1c over the fast blood glucose are its lower intra-individual variability, assessment in non-fasting state and superior in monitoring blood glucose level [6,19]. Preis & Selvin et al, [1,6] has suggested that glycosylated hemoglobin is superior to fasting blood glucose in predicting long-term risk of CAD in non-diabetes. Similar result is reported by Park and colleagues among non-diabetic women [20]. In a cohort of European men, khaw and colleagues [21] reported that HbA1c correlates linearly to subsequent cardiovascular morbidity [21]. The American Diabetes Association suggests that individual with HbA1c concentration of 5.7- 6.4% should be informed of their increased risk for diabetes as well as cardiovascular disease [19, 22-27].

Conclusion

HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality. People at high risk for type II diabetes mellitus should receive lifestyle counseling and if needed pharmacological therapy to reduce their risk of developing hyperglycemia and type II diabetes mellitus but specially to prevent or slow the development of CAD.

References

1. Preis S, Hwang S, Coady S, Pencina M, D Agostino R, et al. (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart study, 1950 to 2005. *Circulation* 119(13): 1728-1735.
2. Husband DJ, Alberti KG, Julian DG (1983) Stress hyperglycemia during acute myocardial infarction: an indicator of pre-existing diabetes *Lancet* 2(8343): 179-181.
3. Wahab N, Cowden E, Pearce N, Gardner M, Merry H, et al. (2002) Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era *J Am Coll Cardiol* 40(10): 1748-1754.
4. Wiviott S, Braunwald E, Angiolillo D, Meisel S, Dalby A, et al. (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel -Thrombolysis in myocardial infarction 38. *Circulation* 118(16): 1626-1636.
5. Li D, Zhao L, Liu M, Du X, Ding W, et al. (1999) Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. *Am heart J* 137(6): 1145-1152.
6. Selvin E, Streffes M, Zhu H, Matsushita K, Wagenknecht L, et al. (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in non-diabetic adults. *N Engl J Med* 362(9): 800-811.
7. Timmer JR, Hoekstra M, Nijsten MW, Van Der Horest IC, Ottervanger JP, et al. (2011) Prognostic value of admission glycosylated hemoglobin and glucose in non-diabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. *Circulation* 124(6): 704-711.
8. Pai JK, Cahill LE, Hu FB, Rexorde KM, Manson JE, et al. (2013) hemoglobin A1c is associated with increased risk of incident coronary heart disease among apparently healthy, non-diabetic men and women. *J Am Heart Assoc* 2(2): e000077.
9. Sewardsen M, Vythilingum S, Jailal I, Becker PJ (1989) Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. *Q J Med* 71(265): 461-466.
10. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, et al. (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and Endocrine Society. *Diabetes Care* 36(5): 1384-1395.
11. Gosselink AT, Liem AL, Reiffers S, Zijlstra F (1998) Prognostic value of predischARGE radionuclide ventriculography at rest and exercise after acute myocardial infarction treated with thrombolytic therapy or primary coronary angioplasty. The Zwolle Myocardial Infarction Study Group. *Clin Cardiol* 21(4): 254-260.
12. DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL (2001) Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol* 87(9): 1035-1038.
13. Li YP, Reid MB (2001) Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. *Curr Opin Rheumatol* 13(6): 483-487.
14. Fujita H, Morita I, Murota S (1999) A possible involvement of in transporter in tumor necrosis factor alpha and cycloheximide-induced apoptosis of endothelial cells. *Mediators Inflamm* 8(4-5): 211-218.
15. Capes S, Hunt D, Malmberg K, Gerstein HC (2000) Stress hyperglycemia and the risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 355(9206): 773-778.
16. Norhammar A, Tenerz A, Nilsson G, Efendic S, Ryden I, et al. (2002) Glucose metabolism in patients with myocardial infarction and no previous diagnosis of diabetes mellitus; a prospective study. *Lancet* 359(9324): 2140-2144.
17. Cakmak M, Cakmak N, Cetemen S, Tanverdi H, Enc Y, et al. (2008) The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. *Can J Cardiol* 24(5): 375-378.
18. Melissa J Gillett (2009) International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: *Diabetes Care* 2009; 32(7) 1327-1334. *Clin Biochem Rev* 30(4): 197-200.
19. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. *Diabetes care* 33(4): 62-69.
20. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S (1996) GHB is better predictor of cardiovascular disease than fasting or post challenge plasma glucose in women without diabetes. The Rancho Bernardo Study. *Diabetes Care* 19(5): 450-456.
21. Khaw K, Wareham N, Luben R, Bingham S, Oakes S, et al. (2001) Glycated haemoglobine, diabetes and mortality in men in Norfolk cohort of European prospective investigation of Cancer and Nutrition (EPIC-Norfolk) *BMJ* 322(7277): 15-18.
22. Ashra f H, Boroumand MA, Amirzadegan A, Talesh SA, Davoodi G (2013) Hemoglobin A1C in non diabetic patients: an independent predictor of coronary artery disease and its severity. *Diabetes Res Clin Pract* 102(3): 225-232.

23. Diabetes Control and complication Trial (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications trial. *Diabetes* 45(10): 1289-1298.
24. Gerrity R, Natarajan R, Nadler J, Kimsey T (2001) Diabetes induced accelerated atherosclerosis in swine. *Diabetes* 50(7): 1654-1665.
25. Ghaffari S, Nadiri M, Pourafkari L, Sepehrvand N, Movasagpoor A, et al. (2014) The predictive value of total neutrophil count and neutrophil/lymphocyte ratio in predicting in-hospital mortality and complications after STEMI. *J Cardiovascular Thorac Res* 6(1): 35-41.
26. Kassaian SE, Goodarznejad H, Boroumand MA, Salarifar M, Masoudkabar F, et al. (2012) Glycosylated hemoglobin (HbA1c) level and clinical outcomes in diabetic patients following coronary artery stenting. *Cardiovascular Diabetology* 11: 82.
27. (2000) Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American college of cardiology Committee for the Redefinition of myocardial infarction. *Eur Heart J* 21(18): 1502-1513.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/CRDOJ.2019.12.555840](https://doi.org/10.19080/CRDOJ.2019.12.555840)

**Your next submission with Juniper Publishers
will reach you the below assets**

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>